Heidelberg University Hospital

A European consortium led by OncoHost has been awarded €2.5 million from the EIC Transition Programme to develop NeutroFlow, a diagnostic test predicting patient response to immune checkpoint inhibitors across five cancer types.

A second-generation BCMA-directed CAR T-cell therapy, MDC-CAR-BCMA001, demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma and AL amyloidosis, achieving a 5/6 overall response rate with 4 complete responses.

Adjuvant gemcitabine-capecitabine (GemCap) demonstrates prolonged overall survival compared to gemcitabine alone in pancreatic adenocarcinoma patients.